TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Real-World study checks tafamidis for rare heart disease in korea
Disease control CompletedThis study looked at how well the drug tafamidis 61mg works for Korean patients with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers tracked 13 patients who were already prescribed the drug in real-world clinics. They measured changes in …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Tiny study checks heart drug safety in india
Disease control CompletedThis study looked at the safety of a drug called Tafamidis (brand name VyndaMx) in 6 people in India with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). In ATTR-CM, faulty proteins build up in the heart and make it harder to pump blood. Researchers …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Stress echo could unmask hidden heart valve disease in amyloidosis patients
Diagnosis CompletedThis study looked at 15 patients with a rare heart condition called wild-type transthyretin amyloid cardiomyopathy (ATTRwt) who also had signs of aortic stenosis. Researchers used dobutamine stress echocardiography—a test that uses a drug to make the heart pump harder while imagi…
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
Phase: NA • Sponsor: Steen Hvitfeldt Poulsen • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC